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The objective of the present investigation was to develop bilayered tablets of lornoxicam to achieve 
biphasic release pattern. A bilayered tablet, consisting of an immediate and controlled release layer, was 
prepared by direct compression technique. The controlled release effect was achieved by using various 
hydrophilic natural, semi synthetic and synthetic controlled release polymers such as xanthan gum, 
hydroxypropyl methylcellulose (HPMC) and polyethylene oxide (PEO) to modulate the release of the 
drug. The in vitro drug release profiles showed the biphasic release behavior in which the immediate 
release (IR) layer containing the lornoxicam was released within 15 minutes, whereas the controlled 
release (CR) layer controlled the drug release for up to 24 h. All the bilayered tablets formulated have 
followed the zero order release with non-Fickian diffusion controlled release mechanism after the initial 
burst release. FTIR studies revealed that there was no interaction between the drug and polymers used 
in the study. Statistical analysis (ANOVA) showed no significant difference in the cumulative amount 
of drug release after 15 min, but significant difference (p < 0.05) in the amount of drug released after 24 
h from optimized formulations was observed. Based on the release kinetic parameters obtained, it can 
be concluded that xanthan gum polymer was suitable for providing a biphasic release of lornoxicam.
Uniterms: Lornoxicam/bilayered tablet/development. Bilayered tablet/biphasic release. Hydrophilic 
polymers/use/drug release. Drugs/controlled release.
O objetivo do presente trabalho foi desenvolver comprimidos bicamada de lornoxicam para atingir 
padrão de liberação bifásica. Preparou-se, por compressão direta, comprimido bicamada, consistindo 
de uma camada de liberação imediata e uma de liberação controlada. A liberação controlada foi obtida 
pelo uso de vários polímeros naturais hidrofílicos, semi-sintéticos e sintéticos, tais como goma xantana, 
hidroxipropilmetil celulose (HPMC) e óxido de polietileno (PEO) para modular a liberação do fármaco. 
Os perfis de liberação in vitro mostraram comportamento bifásico em que a camada de liberação imediata 
(IR) contendo lornoxicam foi liberada em 15 minutos, enquanto a camada de liberação controlada 
(CR) liberou o fármaco em mais de 24 horas, Todos os comprimidos bicamada formulados seguiram a 
liberação de ordem zero com mecanismo de liberação controlada por difusão não fickiana após a liberação 
inicial por erupção. Os estudos de FTIR revelaram que não há interação entre o fármaco e os polímeros 
utilizados no estudo. A análise estatística (ANOVA) não mostrou diferença significativa na quantidade 
acumulada de fármaco após 15 minutos de liberação, mas observou-se diferença significativa (p<0,05) 
na quantidade de fármaco liberado após 24 h nas formulações otimizadas. Com base nos parâmetros de 
cinética de liberação obtidos, pode-se concluir que a goma xantana foi adequada para se atingir liberação 
bifásica de lornoxicam. 
Uniterms: Lornoxicam/comprimido bicamada/desenvolvimento. Comprimido bicamada/liberação 
bifásica. Polímeros hidrofílicos/uso/liberação do fármaco. Fármacos/liberação controlada. 
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INTRODUCTION
Biphasic drug delivery systems are designed to 
release the drug at two different rates or at two different 
time periods i.e. they are either quick/slow or slow/quick. 
A quick/slow release system provides an initial burst 
release of drug followed by a constant rate (ideally) of 
release over a defined period of time. This type of system is 
used primarily when maximum relief needs to be achieved 
quickly, and it is followed by a controlled release phase 
to avoid repeated administration. Whereas release from 
slow/quick is vice versa and it is obtained using multi-
unit dosage forms or compression coated tablets for the 
treatment of those diseases that follow circadian rhythm 
(Kenneth et al., 2003). Non-steroidal anti-inflammatory 
drugs (NSAIDs), antihypertensive, antihistaminic and 
anti-allergic agents (Maggi et al., 1999) are some classes 
of drugs suitable for design of bilayered (biphasic) drug 
delivery systems. Generally, conventional controlled re-
lease dosage forms provide delayed release of drug from 
the dosage form which leads to delay in attaining maxi-
mum therapeutic plasma levels immediately. To modify 
the release of the drug from these systems, the surface 
area exposed to a fluid can be restricted by the addition of 
barrier layers to one or both sides of the tablets (Colombo 
et al., 1990; Qiu et al.,1998; Chidambaram et al., 1998). 
There are several approaches reported to achieve biphasic 
drug delivery, like multi-particulate system (White et al., 
1997; Morita et al., 2000), osmotic pump system (Botti et 
al., 2004; Li et al., 2004), pulsatile drug delivery system, 
compressed matrix core tablet (Eiji et al., 2000) and of 
these bilayered tablet system is a novel approach.
Previously, Luana Perioli et al., 2007 formulated 
a mucoadhesive bilayered tablet of flurbiprofen with 
sustained release for bucaal delivery. The first layer was 
responsible for retention on mucosa and the second layer 
for the buccal drug delivery. Remya et al., 2010 has devel-
oped a robust formulation of bilayered tablets containing 
ibuprofen and methocarbamol using povidone k-30 as 
binder. The main aim for formulation of these tablets was 
to attain the prolonged and repeat action of drug. Sunil 
Reddy et al., 2010 used the concept of bilayered tech-
nology to develop the tablets containing glimepride for 
immediate release using sodium starch glycolate as super 
disintegrant and metformin hydrochloride for sustained 
release by using Hydroxyl propyl methyl cellulose and 
sodium carboxy methyl cellulose as the matrix forming 
polymer, and PVPK-30 as binder. Ajit et al., 2009 designed 
a bilayer regioselective floating tablets to attain a biphasic 
release of atenolol and lovastatin to give immediate release 
of lovastatin and sustained release of atenolol.
Lornoxicam is NSAID of the oxicam class with 
analgesic, anti-inflammatory and antipyretic proper-
ties which belongs to Biopharmaceutical Class II (Low 
solubility and high permeability). The bioavailability of 
lornoxicam is 90% – 100%. Because of its relatively short 
plasma half-life, 3-5 h (Neil et al., 1998), it is prescribed 
to take lornoxicam in divided daily doses either twice or 
thrice daily in order to maintain the therapeutic plasma 
concentration. These characteristics make lornoxicam a 
suitable candidate for developing into bilayered tablet.
In the present study, it is aimed to design, develop 
and characterize a biphasic delivery dosage form as a bi-
layered tablet in which the immediate release by IR layer 
and controlled release by the CR layer using different 
hydrophilic polymers of synthetic (PEO), semisynthetic 
(HPMC) and natural (xanthan gum) origin.
MATERIAL AND METHODS
Material
Lornoxicam, a slightly soluble drug was obtained 
as gift sample from Macleods Pharmaceuticals Ltd., 
Mumbai, India. PEO WSR N 60K was purchased from 
Kemphasol Chemicals, Mumbai, India. HPMC was 
supplied by Colorcon (Orpington, UK) and Xanthan 
gum was purchased from M/s Girijan Co-operative 
Corporation,Visakhapatnam, India. Starch 1500 from 
Reidel Chem., Mumbai, India and polyvinyl pyrrolidone 
(povidone) was obtained from Lab. Chemi. Mumbai, 
India. All other chemicals used were of analytical grade.
Methods
Calculation of the controlled release dose
As per the zero order release principle, the rate of 
delivery must be independent of the amount of drug re-
maining in the dosage form and constant over time. The 
release from the dosage form should follow zero order 
kinetics, as shown by the following Equation 1:
 K0 = Rate in = Rate out = Ke . Cp . Vd Eq. 1
where K0 is the zero order rate constant for drug release 
(amount/time), ke is the first order rate constant of overall 
drug elimination (h–1), Cp is the desired plasma drug level 
(amount/volume), and Vd is the volume of drug distributed 
(Wai-Yip et al., 2000). If the elimination half-life of lor-
noxicam is 3-5 h (ke = 0.693/4.0), Cp is 0.28 mg/L (Neil et 
al., 1998), and Vd is 10.5 L, then K0 is 0.5093 mg/h. For a 
system in which the maintenance dose releases the drug 
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by a zero order process for a specified period of time, the 
total dose is as follows: 
 Dtotal = DI – K0tp + K0td Eq. 2
where DI is the initial dose, K0 is the zero order rate Con-
stant, tp is the time of the peak drug level and td is the total 
time desired for controlled release from single dose (i.e. 
24 h). If the maintenance dose begins to release the drug 
at the time of dosing (t = 0), it will add to that which is 
provided by the initial dose, thus increasing the initial drug 
level. In this case, a correction factor is needed (K0 tp) to 
account for the added drug from the maintenance dose. 
This correction factor is the amount of drug provided 
during the period from t = 0 to the time of the peak drug 
level, tp. If DI is 3.24 mg, K0 is 0.5093 mg/h, tp is 1.5 h, 
and td is 24 h, then as per Equation 2 the total dose would 
be 15.46 mg of lornoxicam. From the above calculations 
total dose obtained for controlled release of lornoxicam 
for 24 h is 15.46 mg. The total dose was rounded to 15.5 
mg for the convenience.
Preparation and characterization of bilayer tablets
The dose in the formulation for IR tablet was 3.25 
mg and the maintenance dose or CR dose (12.25 mg) of 
lornoxicam was calculated as per above given formula in 
Equation 2.
Formulation of the immediate release layer
The IR layer was prepared by passing the accurately 
weighed drug, starch 1500 and 5% PVP as a dry binder 
through # 40 (420 µm ASTM) as per the formulae given 
in Table I. The sieved blend was transferred to a poly bag 
and mixed for 5 minutes. The obtained blend was lubri-
cated for 2 minutes with magnesium stearate and brilliant 
lake red passed thorough # 60 (250 µm ASTM) and # 100 
TABLE I - Formulae of immediate release layer
Ingredients Quantity per tablet (mg)
Lornoxicam 3.24
Starch 1500 43.76
PVP 2.50
Magnesium stearate 0.50
Brilliant lake red q.s.
Total 50
TABLE II - Formulae of controlled release layer
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Lornoxicam 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22
PEO 6.11 12.22 18.33 - - - - - -
HPMC K15M - - - 6.11 12.22 18.33 - - -
Xanthan gum - - - - - - 6.11 12.22 18.33
PVP 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5
Starch 1500 46.06 39.95 33.84 46.06 39.95 33.84 46.06 39.95 33.84
Magnesium stearate 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
Talc 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4
Total weight 70 70 70 70 70 70 70 70 70
(150 µm ASTM) respectively. Brilliant lake red was added 
to differentiate the IR layer from the CR layer. 
Formulation of the controlled release layer
The CR layer was prepared by blending the drug 
and the controlled release polymer (PEO, HPMC K15M, 
Xanthan gum ) individually, uniformly along with dilu-
ent and PVP K30 as a dry binder in a ploy bag as per the 
formulae given in Table II after sifting them through # 40 
(420 µm). The resulting blend was lubricated with talc 
and magnesium stearate passed through # 60 (250 µm).
Precompression studies of the prepared blend to be 
compressed into a tablet
Prior to the compression of the formulation blends 
into tablets, flow properties of the powders should be de-
termined to check its suitability for compression.
Angle of repose (AR), compressibility Index (CI) 
and Hausner’s ratio (HR) were used to characterize flow 
properties of the blends. The flowability of a powder is of 
critical importance in the production of pharmaceutical 
dosage forms in order to reduce dose variations (Kulkarni 
et al., 2010; Fahmy et al., 2008; Amidon et al., 2009; 
USP32-NF27, 2009; Kulkarni et al., 2010; Bhise et al., 
2008; Shah et al., 2008).
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Bulk density
Bulk density of a powder is the ratio of the mass of 
the powder to the volume occupied by the loose powder 
bed. The unit volume includes the spaces between the 
particles and the envelope volumes of the particles them-
selves.
An amount of powder equivalent to 15 g was ac-
curately weighed and placed in a 50 mL volumetric cyl-
inder without compaction and the volume occupied was 
measured and the initial bulk density was calculated by 
the following equation. Each experiment was performed 
in triplicate and calculated using Equation 3.
 rbulk = M/Vbulk Eq. 3
where, rbulk = bulk density, M = mass of the powder and 
Vbulk = Initial volume of powder
Tapped density
Tapped density of a powder is the ratio of the mass of 
the powder to the volume occupied by the powder after a 
fixed number of taps (100). The tapped density of a powder 
represents its random dense packing.
An amount of each powder of 15 g was accurately 
weighed and placed in a 50 mL volumetric cylinder. Then 
the cylinder was tapped by raising it to a height of 12–14 
mm and then allowing it to fall under its own weight. The 
final volume was recorded and the final tapped density was 
calculated by the following Equation 4. Each experiment 
was performed in triplicate.
 rtap = M/Vtap Eq. 4
where,  rtap = tapped density, M = mass of the powder and 
Vtap = Volume of powder on tapping
The bulk and tapped densities were used to calculate 
the CI and the HR.
Carr’s compressibility index
Carr’s compressibility index (CI) of the powder was 
found by using the following Equation 5.
  Eq. 5
CI value can reflect the ease of powder consolidation. A 
higher CI values indicates its poor flow.
Hausner’s ratio
The powder’s Hausner’s ratio (HR) is expressed 
as HR value reflects inter particulate friction. A high HR 
value means poor flow calculated using Equation 6.
  Eq. 6
Angle of repose
Angle of repose (AR) has been used as an indirect 
method of quantifying powder flowability. AR for the 
blend of each formulation was determined by the fixed 
funnel method.
A glass funnel was secured with its tip positioned at a 
fixed height (h) above a graph paper placed on a horizontal 
surface. The powders were carefully poured through the 
funnel until the apex of the conical pile so formed just 
touched the tip of the funnel. The mean radius (r) of the 
base of the powder cone was determined and the AR (θ) 
was calculated as follows:
 tan q = h/r Eq. 7
where, h = height of the conical pile and r = radius of the 
conical pile.
The procedure was done in triplicate and the average 
AR was calculated for each powder. AR is a characteristic 
property related to inter particulate friction or resistance 
to movement between particles. A general scale of powder 
flow using the CI, HR and AR are given in Table III.
Compression of the bilayer tablet
Initially the die was filled with CR blend and pre-
compressed using 16 station, single rotary tablet compres-
sion machine (Cadmach Machinery Co.Pvt. Ltd., India) 
equipped with 6 mm round concave punches. Upon this 
precompressed CR layer, weighed quantity of IR blend 
was transferred manually followed by compression ob-
taining a bilayered tablet having hardness in the range of 
6-8 kgcm-2.
Evaluation of bilayered tablets
The prepared bilayered tablets were subjected to 
TABLE III - Scale of flowability determined by different methods
Flow property AR (θº) CI (%) HR
Excellent 25–30 ≤ 10 1.00–1.11
Good 31–35 11–15 1.12–1.18
Fair (aid not needed) 36–40 16–20 1.19–1.25
Passable (may hang up) 41–45 21–25 1.26–1.34
Poor (must agitate, 
vibrate)
46–55 26–31 1.35–1.45
Very poor 56–65 32–37 1.46–1.59
Very, very poor > 66 > 38 > 1.60
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quality control tests such as uniformity of weight, friability 
test, hardness, drug content and in vitro dissolution studies.
Uniformity of weight
According to Indian Pharmacopoeia (I.P.) (IP2007, 
2008), 20 tablets were selected at random, weighed to-
gether and then individually. The mean and the standard 
deviation were determined. 
Prepared tablets complies the test if not more than 
two of the individual weights deviate from the average 
weight (>250 mg) by more than the percentage (5%) and 
none deviate more than twice that percentage.
Friability
The friability test (IP2007, 2008) was carried out 
in dual chamber friabilator (Electrolab, India). Tablets 
equivalent to 6.5 g were weighed (W0) initially and put in 
a rotating drum. Then, they were subjected to 100 falls of 
6 inches height (25 rpm for four min). After completion 
of rotations, the tablets were dedusted by using camel 
hair brush and weighed (W). The percent loss in weight 
or friability was calculated by the formula given below. 
Hardness (Banker et al., 2009)
Tablets should be sufficiently hard to resist breaking 
during normal handling and yet soft enough to disintegrate 
properly after swallowing. Five tablets were randomly 
selected and the hardness of each tablet was measured 
using Monsanto hardness tester. The mean hardness was 
determined and expressed in kgcm-2.
Determination of drug content 
From each batch of prepared tablets, 10 tablets were 
randomly collected and powdered (IP2007, 2008). Powder 
equivalent to 15.46 mg of lornoxicam was weighed accu-
rately from each batch and were transferred separately to 
a 100 mL volumetric flask. Volume was made up to 100 
mL with pH 7.4 phosphate buffer and subjected for vortex 
mixing and sonication for dissolving the drug. Appropri-
ate dilutions were made with pH 7.4 phosphate buffer and 
the amount of lornoxicam was analyzed using a validated 
method at 378 nm using a double beam UV/visible spec-
trophotometer (Elico Ind Ltd, India) (Bettini et al., 2001). 
The drug content was calculated using Equation 8.
 Eq. 8
In vitro dissolution study
The in vitro release tests were performed using 
LABINDIA, Disso 2000, according to the US Pharmaco-
poeia 27, the compressed bilayered tablets were introduced 
into dissolution medium. A 900 mL of phosphate buffer 
pH 7.4 was used as dissolution medium, rotational speed 
of the paddle was set at 50 rpm at 37 ± 0.5 ºC. Aliquots 
(5 mL each) were withdrawn at predetermined time inter-
vals by means of a syringe fitted with a 0.45 µm pre-filter 
and immediately replaced with 5 mL of fresh medium 
maintained at 37±0.5 °C. The samples were analyzed for 
lornoxicam at 378 nm using a double beam UV/visible 
spectrophotometer (Elico Ind Ltd, India). All the dissolu-
tion experiments were carried out in triplicate.
Release kinetics
The analysis of drug release mechanism from a phar-
maceutical dosage form is an important but complicated 
process and is practically evident in the case of matrix 
systems. As a model-dependent approach, the dissolution 
data was fitted to five popular release models such as zero-
order, first-order, Higuchi, Hixon-Crowel and Korsmeyer 
Peppas equations. The order of drug release from matrix 
systems was described by using zero order kinetics or first 
orders kinetics and the mechanism of drug release by using 
Higuchi and Hixon-Crowel equation.
Zero order release kinetics is (Lazarus et al., 1961) 
defined as a linear relationship between the fractions of 
drug released versus time. A plot of the fraction of drug 
released against time will be linear if the release obeys 
zero order release kinetics. It is given by Equation 9 below:
 Q = k0t Eq. 9
where, Q is the fraction of drug released at time t and k0 is 
the zero order release rate constant.
In first order release kinetics (Wagner et al., 1969) 
Wagner assumed that the exposed surface area of a tablet 
decreased exponentially with time during dissolution 
process, this suggests that drug release from most of the 
slow release tablets could be described adequately by ap-
parent first-order kinetics. First order kinetics is defined 
by Equation 10 below:
 ln (1-Q) = −k1t Eq. 10
where, Q is the fraction of drug released at time t and k1 is 
the first order release rate
constant. Thus, a plot of the logarithm of the fraction 
of drug remained against time will be linear if the release 
obeys first order release kinetics.
Higuchi equation (Higuchi et al., 1963) defines a 
linear dependence of the active fraction released per unit 
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of surface (Q) on the square root of time. It is defined by 
Equation 11 below:
 Q = k2t½ Eq. 11
where, k2 is the release rate constant. Hence, a plot of the 
fraction of drug released against square root of time will be 
linear if the release obeys Higuchi equation. This equation 
describes drug release as a diffusion process based on the 
Fick’s law, square root time dependent.
Erosion equation (Korsmeyer et al.,1983) defines 
the drug release based on tablet erosion alone (See Equa-
tion 12).
 Q = 1- (1-K3t)3 Eq. 12
where, Q is the fraction of drug released at time t, K3 is 
the release rate constant. Thus, a plot between [1-(1-Q)1/3 
] against time will be linear if the release obeys erosion 
equation. 
In order find out the mechanism of drug release, first 
60% drug release data were fitted in Korsmeyer Peppas 
model in Equation13
 Mt / M8 = K4tn Eq. 13
where Mt / M8 is a fraction of drug released at time, t, K4 is 
the release rate constant and n is the release exponent. The 
n value is used to characterize different release for cylin-
drical shaped matrices. For the case of cylindrical tablets, 
0.45 = n corresponds to a Fickian diffusion mechanism, 
0.45 < n < 0.89 to non-Fickian transport, n = 0.89 to Case 
II (relaxational) transport, and n > 0.89 to super case II 
transport (Peppas et al., 1985).
Fourier Transform Infrared Spectroscopy
Infrared spectroscopy was conducted using a Shi-
madzu FTIR 8300 Spectrophotometer and the spectrum 
was recorded in the region of 4000 to 400 cm-1. The pro-
cedure consisted of dispersing a sample (drug and drug 
resinate mixture, 1:1 ratio) in KBr (200-400 mg) and 
compressing into discs by applying a pressure of 5 tons 
for 5 min in a hydraulic press. The pellet was placed in the 
light path and the spectrum was obtained. Spectra were 
recorded in duplicate for each of sample.
RESULTS AND DISCUSSION
Precompression studies of the prepared blend to 
be compressed into a tablet
Powder flow properties are the important parameters 
which are crucial in processing operations such as mixing, 
flow of blend from hoppers to the turret for compression. 
One of the major problems encountered with these poor 
flowing powders in pharmaceutical industry is inconsistent 
and uniform flow from the hoppers. The angle of repose of 
the all blends (F1 to F9) was found to be ≤ 25o indicating 
excellent properties. The Carr’s index and Hausner’s ratio 
of the all blends was found to be ≤ 20 % and 1.20-1.25 
indicating good flow properties. Blend of all the batches 
used for compression of core tablets exhibited good flow 
and compression properties as the excipients used for the 
formulations were of directly compressible grade. The 
results in Table IV had shown that the direct compression 
method can be used for the compression of tablets.
Evaluation of bilayered tablets
The physical attributes of the tablet were found to be 
satisfactory. Typical tablet defects, such as capping, chip-
ping, and picking, were not observed. Tablet properties 
like weight variation, thickness, hardness, friability and 
drug content of each batch was represented in Table V. All 
TABLE IV - Flow properties of the blend used for compression of core tablet
Formulation Carr’s index (CI) Hausner’s ratio (HR) Angle of repose (AR)
F1 15.6±0.05 1.22±0.02 22.0±0.02
F2 18.8±0.04 1.21±0.02 23.2±0.05
F3 20.9±0.02 1.24±0.05 24.4±0.03
F4 15.0±0.03 1.19±0.03 22.1±0.03
F5 17.3±0.02 1.24±0.04 23.8±0.04
F6 19.6±0.06 1.23±0.03 24.2±0.05
F7 16.6±0.03 1.20±0.02 21.3±0.02
F8 18.3±0.05 1.22±0.05 22.5±0.04
F9 20.6±0.04 1.24±0.04 24.6±0.02
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TABLE V - Physical parameters of the bilayered tablets
Formulations Thickness*
 
(mm) 
Uniformity of weight 
(mg)** 
Drug Content* 
(%) 
Hardness*
(kg/cm2) 
Friability 
(%) 
F1 3.51± 0.02 124.8± 3.03 100.1± 1.98 6.57± 0.15 0.79± 0.02 
F2 3.53 ± 0.04 122.0± 2.12 98.60± 1.3 6.87± 0.15 0.82± 0.05 
F3 3.54± 0.05 123.4± 2.70 102.5± 2.9 6.97± 0.21 0.84± 0.06 
F4 3.54± 0.04 122.0± 2.35 99.83± 2.35 7.03± 0.25 0.75± 0.03 
F5 3.53± 0.04 120.6± 1.52 97.87± 1.34 7.23± 0.25 0.84± 0.05 
F6 3.52 ± 0.03 123.0± 3.08 103.03± 2.83 7.50± 0.20 0.87± 0.04 
F7 3.53 ± 0.04 123.8± 2.86 101.03± 1.58 6.63± 0.15 0.71± 0.12 
F8 3.55 ± 0.05 121.4± 2.51 99.83± 2.35 6.87± 0.15 0.83± 0.06 
F9 3.52 ± 0.03 120.6 ± 1.52 100.83± 1.55 7.10± 0.20 0.89± 0.06
* All values are expressed as mean ±s.d., n = 10; ** All values are expressed as mean ± s.d., n = 20
batches passed the weight variation test and found to be 
within range (±7.5%). Friability of all batches were found 
less than 1% and indicates that tablet surfaces are strong 
enough to withstand mechanical shock or attrition during 
storage and transportation and until they are consumed. 
Hardness of the tablet was found to be 6.5-7.5 kgcm-2. 
Thickness and diameter were found to be fixed during 
the compression cycle; values were 3.5 mm, and 6 mm, 
respectively. Drug content of all batches was found within 
the limit (90–110%). Low s.d. values in drug content in-
dicated uniformity of drug distribution in all the prepared 
tablets. Thus, the prepared bilayered tablets of lornoxicam 
were found to be of good quality fulfilling all the official 
compendia for tablets.
In vitro dissolution study
Bilayered tablets were developed using different 
retarding polymers (PEO WSR N60K, HPMC K 15 M 
and Xanthan gum) in different concentrations (0.5%, 1.0% 
and 1.5% w/w). More than 99% of the drug was released 
from all the tablets. The polyether chains present in PEO 
can form strong hydrogen bonds upon contact with water 
and therefore, when solid matrices brought into contact 
with an aqueous medium, the polymer tends to hydrate, 
forming a superficial gel which eventually erodes as the 
polymer dissolves. As the polymer dissolves the fresh 
surfaces are exposed to the dissolution medium, only once 
the gel layer is formed it starts controlling the diffusion 
of the polymer (Petrovic et al., 2009). The tablets F1, F2 
and F3 prepared with PEO released more than 99% of the 
drug in 5 hrs, 8 hrs and 11 hrs respectively. F4, F5 and F6 
formulations with HPMC as retarding polymer released 
more than 99% of the drug at the end of 5 hrs, 11 hrs and 
16 hrs respectively. The results have also shown that the 
presence of more polymer at the surface resulted in in-
stant formation of a gel layer upon contact with medium, 
which prevented initial burst of drug release. This supports 
Pham et al, (1994) observation that for relatively water 
insoluble drugs and/or lower viscosity grades of HPMC, 
polymer dissolution plays an important role in regulating 
drug release.
When xanthan gun was used in formulations F7, 
F8 and F9, maximum drug release was observed in 5 h, 
16 h and 24 h respectively. Formulation F9 prepared with 
xanthan gum as a rate retarding polymer was selected as 
the optimized formulation keeping in view the minimum 
amount of xanthan gum required to control the release for 
a period of 24 h. From all the formulations it was observed 
that, loading dose of the lornoxicam was released from the 
IR layer within the first 15 min of the dissolution study. 
Further release of lornoxicam was studied for 24 hours. 
Respective dissolution profiles of all the formulations are 
given in Figure 1
All the polymers used in the study are hydrophilic 
but the difference in the percentage drug release was due 
to the swelling nature of the polymers. Higher the swell-
ing nature of the polymer, higher was the ability to retard 
the drug release. As the concentration of the polymer was 
increased the % drug release decreased for all the poly-
mers. The order of retarding capacity of the polymers was 
in the following order xanthan gum>HPMC K 15 M>PEO 
N 60K, which also states that the swelling capacity of 
xanthan gum was more than the other polymers.
Release kinetics
The drug release of lornoxicam from all the formu-
lations F1 to F9 followed zero order kinetics which was 
indicated by higher ‘r’ values of zero order release model, 
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when compared to those of first order release model. The 
‘r’ values ranged from 0.9463 – 0.9936 and the rate order 
values are shown in Table VI.
The relative contributions of drug diffusion and ero-
sion to drug release were further confirmed by subjecting 
the dissolution data to Higuchi model and Hixon Crowell 
model. Release of the drug from a matrix tablet contain-
ing hydrophilic polymers generally involves diffusion. 
It was found that all the formulations F1 to F9 followed 
diffusion mechanism as the ‘r’ values (0.9527 to 0.9942) 
were higher than for erosion release. The ‘n’ value for the 
diffusion release observed was less than 0.5 indicated that 
all the formulations Non-Fickian diffusion mechanism. All 
the formulations F1 to F9 followed Zero order release with 
Non-Fickian diffusion mechanism. The desired targeted 
release 24 hrs was achieved by formulation F9 which was 
prepared by using Xanthan gum in (1:1.5) ration of drug 
and polymer and also as the polymer is of natural origin 
which is of great advantageous over synthetic polymers 
(PEO WSR N60K) and semi synthetic polymers (HPMC 
K 15M), it is considered as the best formulation. Analysis 
of variance (ANOVA) showed no significant difference 
in the amount of drug released after 15 min for all the for-
mulations, whereas significant differences (p<0.05) was 
observed for optimized formulations when compared to 
the other formulations after 24 h.
Fourier Transform Infrared Spectroscopy
Pure lornoxicam spectra showed characteristic peaks 
at 3090.31 cm–1 (C-H stretching for hetero aromatic func-
tional group), 1596.79 cm-1 (N-H bending group), 1643.29 
cm–1 (C=O stretching). as shown in Figure 2.
Optimized formulations F9 also exhibited the char-
acteristic peaks of lornoxicam with no additional peaks 
observed in the spectra, indicating retention of chemical 
identity of lornoxicam. However, intensity of peaks cor-
responding to the drug was reduced or broadened in the 
optimized formulations possibly due to the mixing of other 
excipients as shown in Figure 3. The FTIR spectra data 
confirmed that xanthan gum did not alter the performance 
characteristics indicating their compatibility of the drug.
CONCLUSIONS
There is no controlled release tablet or bilayered 
tablet marketed dosage form of lornoxicam, there is only 
immediate release tablet available which cannot fulfill the 
criteria to treat chronic pain. This is possible by formu-
lating a biphasic release system which was achieved by 
bilayered tablet characterized by an initial rapid release by 
the IR layer followed by controlled release of drug from 
FIGURE 1 - In vitro release profiles of lornoxicam from 
bilayered tablet formulations (F1 to F9).
TABLE VI - Kinetic values obtained from different plots of formulations F1 to F9
Formulations
Zero order plots First-order plots Higuchi’s plots Erosion plots Peppas plots
 r ko r k1 R r n r
F1 0.9639 13.42 0.8560 1.38 0.9919 0.9356 0.4445 0.9923
F2 0.9892 7.900 0.8127 0.557 0.9942 0.8926 0.3577 0.9942
F3 0.9758 7.57 0.8309 0.490 0.9849 0.9399 0.4901 0.9853
F4 0.9463 14.15 0.9243 1.16 0.9937 0.9609 0.4573 0.9638
F5 0.9936 6.98 0.9446 0.276 0.9805 0.8913 0.4165 0.9715
F6 0.9897 4.54 0.8810 0.126 0.9527 0.8144 0.3724 0.9527
F7 0.9698 15.10 0.9000 0.962 0.9899 0.9661 0.4785 0.9759
F8 0.9924 5.01 0.8205 0.240 0.9852 0.9047 0.4325 0.9814
F9 0.9747 3.62 0.8527 0.232 0.9820 0.9527 0.4084 0.9752
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FIGURE 2 - FTIR spectra of (a) pure lornoxicam, (b) xanthan gum and (c) F9 formulation.
CR layer of bilayered tablet from the optimized formula-
tion F9 which consists of xanthan gum a natural polymer 
used in 1:1.5 ratio of drug and polymer ratio. This result 
obtained was encouraging as xanthan gum has prolonged 
the release for 24 hrs which is natural in origin. Drug re-
lease is dependent on both the type and amount of polymer 
in the tablet. This biphasic release surmount the major 
disadvantages of controlled release matrix tablets by pro-
viding an additional initial burst release (i.e. loading dose 
form the IR layer) within 15 min followed by a constant 
release from controlled release layer over a defined period 
of time. In the light of the above, it can be concluded that 
bilayer tablet technology can be significantly used for the 
treatment of chronic diseases caused by pain. 
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